Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

The global veterinary biologics market is on a robust growth trajectory, with its valuation expected to reach USD 13,140.6 ...

October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and ...

FRANKFURT (Reuters) – Denmark’s Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration’s Breakthrough Therapy for the review of their ...